FI94352C - Förfarande för framställning av peptid, som hindrar bindningen vid T-4-reseptorer och med immunogen verkan - Google Patents
Förfarande för framställning av peptid, som hindrar bindningen vid T-4-reseptorer och med immunogen verkan Download PDFInfo
- Publication number
- FI94352C FI94352C FI885630A FI885630A FI94352C FI 94352 C FI94352 C FI 94352C FI 885630 A FI885630 A FI 885630A FI 885630 A FI885630 A FI 885630A FI 94352 C FI94352 C FI 94352C
- Authority
- FI
- Finland
- Prior art keywords
- thr
- ser
- tyr
- peptide
- asn
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 15
- 230000027455 binding Effects 0.000 title description 24
- 102000004196 processed proteins & peptides Human genes 0.000 title description 20
- 150000001413 amino acids Chemical group 0.000 claims description 18
- KVPFYRAFNZKJSD-CPXLMRBJSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 KVPFYRAFNZKJSD-CPXLMRBJSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- PZHJLTWGMYERRJ-SRVKXCTJSA-N Ser-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O PZHJLTWGMYERRJ-SRVKXCTJSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 25
- 241000725303 Human immunodeficiency virus Species 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000012528 membrane Substances 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 241000282693 Cercopithecidae Species 0.000 description 13
- 108010071384 Peptide T Proteins 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 101710090322 Truncated surface protein Proteins 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 101710121417 Envelope glycoprotein Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 108070000030 Viral receptors Proteins 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 108010083930 HIV Receptors Proteins 0.000 description 2
- 102000006481 HIV Receptors Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- PZUOEYPTQJILHP-STHAYSLISA-N (2r,3s)-2-amino-3-hydroxybutanamide Chemical compound C[C@H](O)[C@@H](N)C(N)=O PZUOEYPTQJILHP-STHAYSLISA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- IWHCAJPPWOMXNW-ZESMOPTKSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)pr Chemical compound C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-ZESMOPTKSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- -1 N-protected amino Chemical class 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 241000341971 Peplis Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 108010078940 peptide T (4-8) Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- IWHCAJPPWOMXNW-LYKMMFCUSA-N peptide t Chemical group C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-LYKMMFCUSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (11)
1. Förfarande för framställning av en terapeutiskt användbar peptid med formeln I: 5 X-Ra-Ser-Thr-Thr-Thr-Asn-Tyr-Rb-X (I) där R“ är en aminoterminal grupp Ala- eller D-Ala-, Rb är en karboxltermlnal grupp -Thr eller -Thr-amid, 10 och X är Cys eller ena eller bäda X saknas, eller av en peptid med formeln II: X-R1-R2-R3-R4-R5-X (II) 15 där R1 är en aminoterminal grupp Thr-, Ser-, Asn-, Leu-, Ile-, Arg- eller Glu-, R2 är Thr, Ser eller Asp,
20 R3 är Thr, Ser, Asn, Arg, Gin, Lys eller Trp, R4 är Tyr, och R5 är en karboxiterminal aminosyragrupp, motsvarande D-aminosyra, motsvarande amidderivat eller R5 saknas, och X är Cys eller ena eller bäda X saknas, förutsatt 25 dock, att peptiden inte är Ser-Thr-Asn-Tyr-Thr, P · ·’ eller fysiologiskt godtagbara salter därav, känne- t e c k n a t därav, att man a) förankrar den N-skyddade formen av den karboxi-terminala aminosyran vid ett harts, 30 b) avlägsnar aminogruppens skyddsgrupp, c) tillsätter följande aminosyra i skyddad form och kopplar den tili föregäende aminosyra d) upprepar skedena b) och c) för varje tillsatt aminosyra och 35 e) lösgör den färdiga peptiden frän hartset. « 94552 21
2. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att man framställer en peptid med formeln II, där R1 är Thr-, Ser- eller Asn-,
5 R3 är Thr, Ser, Asn eller Arg, ooh R5 är -Thr, -Arg eller -Gly.
3. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att man framställer en peptid med formeln II, vilken saknar R5. 10
4. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att man framställer Cys-R1-R2-R3-R4-R5-Cys.
5. Förfarande enligt patentkrav 1, känne-t e c k n a t därav, att man framställer 15 Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr, Thr-Thr-Asn-Tyr-Thr, Ser-Ser-Thr-Tyr-Arg, Asn-Thr-Ser-Tyr-Thr, Thr-Thr-Ser-Tyr-Thr 20 Asn-Thr-Ser-Tyr-Gly, Ser-Thr-Asn-Tyr-Arg, Ser-Ser-Arg-Tyr-Arg, Thr-Thr-Ser-Tyr-Ser eller Cys-Thr-Thr-Asn-Tyr-Thr-Cys. •
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI943795A FI99115C (sv) | 1986-06-03 | 1994-08-18 | Peptider, som reagerer med antikroppar mot en antigen, som binds vid T4-receptores, och diagnostisk användning därav |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86991986A | 1986-06-03 | 1986-06-03 | |
| US86991986 | 1986-06-03 | ||
| US87858686A | 1986-06-26 | 1986-06-26 | |
| US87858686 | 1986-06-26 | ||
| US4814887A | 1987-05-11 | 1987-05-11 | |
| US4814887 | 1987-05-11 | ||
| PCT/US1987/001270 WO1987007613A1 (en) | 1986-06-03 | 1987-05-27 | Small peptides which inhibit binding to t-4 receptors and act as immunogens |
| US8701270 | 1987-05-27 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI885630A FI885630A (sv) | 1988-12-02 |
| FI885630A0 FI885630A0 (sv) | 1988-12-02 |
| FI94352B FI94352B (sv) | 1995-05-15 |
| FI94352C true FI94352C (sv) | 1995-08-25 |
Family
ID=27367286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI885630A FI94352C (sv) | 1986-06-03 | 1988-12-02 | Förfarande för framställning av peptid, som hindrar bindningen vid T-4-reseptorer och med immunogen verkan |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JP2680011B2 (sv) |
| KR (1) | KR930008448B1 (sv) |
| AU (1) | AU604719B2 (sv) |
| CA (1) | CA1341066C (sv) |
| DE (1) | DE3787927T2 (sv) |
| DK (1) | DK173667B1 (sv) |
| ES (1) | ES2061497T3 (sv) |
| FI (1) | FI94352C (sv) |
| HU (1) | HUT48907A (sv) |
| IE (1) | IE61725B1 (sv) |
| IL (1) | IL82719A (sv) |
| MX (1) | MX172337B (sv) |
| NO (1) | NO176022C (sv) |
| NZ (1) | NZ220485A (sv) |
| PT (1) | PT84992B (sv) |
| WO (1) | WO1987007613A1 (sv) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007016573A (es) * | 2005-06-23 | 2008-10-17 | Rapid Pharmaceuticals Inc | Vacunas y peptidos terapeuticos. |
| CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
-
1987
- 1987-05-27 KR KR1019880700115A patent/KR930008448B1/ko not_active IP Right Cessation
- 1987-05-27 JP JP62503520A patent/JP2680011B2/ja not_active Expired - Fee Related
- 1987-05-27 HU HU873289A patent/HUT48907A/hu unknown
- 1987-05-27 AU AU75408/87A patent/AU604719B2/en not_active Ceased
- 1987-05-27 CA CA000538202A patent/CA1341066C/en not_active Expired - Fee Related
- 1987-05-27 WO PCT/US1987/001270 patent/WO1987007613A1/en active IP Right Grant
- 1987-05-28 NZ NZ220485A patent/NZ220485A/xx unknown
- 1987-05-28 IE IE138887A patent/IE61725B1/en not_active IP Right Cessation
- 1987-05-29 IL IL82719A patent/IL82719A/xx not_active IP Right Cessation
- 1987-06-02 PT PT84992A patent/PT84992B/pt unknown
- 1987-06-03 DE DE87304939T patent/DE3787927T2/de not_active Expired - Fee Related
- 1987-06-03 MX MX006751A patent/MX172337B/es unknown
- 1987-06-03 ES ES87304939T patent/ES2061497T3/es not_active Expired - Lifetime
-
1988
- 1988-02-02 DK DK198800532A patent/DK173667B1/da active IP Right Grant
- 1988-02-03 NO NO880479A patent/NO176022C/no unknown
- 1988-12-02 FI FI885630A patent/FI94352C/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK53288A (da) | 1988-02-02 |
| PT84992A (en) | 1987-07-01 |
| PT84992B (pt) | 1990-03-08 |
| AU604719B2 (en) | 1991-01-03 |
| IE871388L (en) | 1987-12-03 |
| NO880479L (no) | 1988-02-03 |
| AU7540887A (en) | 1988-01-11 |
| CA1341066C (en) | 2000-08-01 |
| FI885630A (sv) | 1988-12-02 |
| MX172337B (es) | 1993-12-14 |
| DE3787927D1 (de) | 1993-12-02 |
| NZ220485A (en) | 1989-08-29 |
| FI885630A0 (sv) | 1988-12-02 |
| HUT48907A (en) | 1989-07-28 |
| WO1987007613A1 (en) | 1987-12-17 |
| FI94352B (sv) | 1995-05-15 |
| KR880701247A (ko) | 1988-07-26 |
| IL82719A0 (en) | 1987-11-30 |
| DE3787927T2 (de) | 1994-03-03 |
| NO880479D0 (no) | 1988-02-03 |
| JP2680011B2 (ja) | 1997-11-19 |
| IL82719A (en) | 1992-11-15 |
| JPH01502659A (ja) | 1989-09-14 |
| NO176022C (no) | 1995-01-18 |
| DK173667B1 (da) | 2001-05-28 |
| KR930008448B1 (ko) | 1993-09-04 |
| NO176022B (no) | 1994-10-10 |
| IE61725B1 (en) | 1994-11-30 |
| ES2061497T3 (es) | 1994-12-16 |
| DK53288D0 (da) | 1988-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hussey et al. | A soluble CD4 protein selectively inhibits HIV replication and syncytium formation | |
| US5276016A (en) | Small peptides which inhibit binding to T-4 receptors and act as immunogens | |
| WO1989003222A1 (en) | Soluble human cd4 fragments and uses therefor | |
| US5603933A (en) | CD4 peptides for binding to viral envelope proteins | |
| EP0249390A2 (en) | Synthetic peptides related to the HIV glycoprotein gp 120 | |
| HU214439B (hu) | Eljárás HIV-fertőzések kezelésére alkalmas monoklonális antitestek és peptidek, valamint ezeket tartalmazó gyógyászati készítmények és vakcinák előállítására | |
| EP0344006A2 (en) | Peptides that block the binding of hiv-1 to th CD4 receptor protein | |
| CS68091A2 (en) | Synthetic polypeptides | |
| US7374875B2 (en) | Peptides having affinity for the gp120 viral protein and use thereof | |
| EP0249394B1 (en) | Small peptides which inhibit binding to T-4 receptors and act as immunogens | |
| US5346989A (en) | Peptides for use in induction of T cell activation against HIV-1 | |
| FI94352C (sv) | Förfarande för framställning av peptid, som hindrar bindningen vid T-4-reseptorer och med immunogen verkan | |
| AU2787489A (en) | Anti-retroviral agent | |
| AU1906592A (en) | Peptides for use in induction of t cell activation against hiv-1 | |
| AP96A (en) | Small peptides which inhibit binding to T-4 receptors and act as immunogens. | |
| FI99115B (sv) | Peptider, som reagerer med antikroppar mot en antigen, som binds vid T4-receptores, och diagnostisk användning därav | |
| NO880446L (no) | Smaa peptider som inhiberer binding til t-4-reseptorer. | |
| JP3725899B2 (ja) | Ｈｉｖに対して使用するための多分岐ペプチド構築物 | |
| JP3725899B6 (ja) | Ｈｉｖに対して使用するための多分岐ペプチド構築物 | |
| WO1998011137A1 (en) | Use of proteins as anti-retroviral agents | |
| WO1991013911A1 (en) | Peptide inhibitor of human immunodeficiency virus infection blocks virus interactions with a novel cellular receptor | |
| MXPA99003380A (en) | Compositions and methods for treating viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: THE UNITED STATES OF AMERICA, AS |
|
| MA | Patent expired |